RG2833 (RGFP109) is primarily researched for its potential therapeutic applications in neurological and psychiatric disorders. It functions as a histone deacetylase (HDAC) inhibitor, specifically targeting HDAC1 and HDAC3, which are involved in gene expression regulation. This mechanism makes it a candidate for treating conditions like Huntington's disease, where it has shown promise in preclinical studies by improving motor function and reducing neurodegeneration. Additionally, it is being explored for its potential in addressing cognitive impairments and mood disorders, as HDAC inhibition can enhance synaptic plasticity and memory formation. It is also under investigation for cancer therapy, where it may inhibit tumor cell growth and promote apoptosis. Research is ongoing to evaluate its efficacy and safety in clinical settings.